Proteomic and metabolomic profiling reveals time-dependent changes in hippocampal metabolism upon paroxetine treatment and biomarker candidates

Journal of Psychiatric Research

Volumn 47, Issue 3, 2013, Pages 289-298

  Webhofer, Christian ^a,b   Gormanns, Philipp ^a   Reckow, Stefan ^a   Lebar, Maria ^a   MacCarrone, Giuseppina ^a   Ludwig, Tonia ^a   Pütz, Benno ^a   Asara, John M ^c   Holsboer, Florian ^a   Sillaber, Inge ^a,d   Zieglgänsberger, Walter ^a,b   Turck, Christoph W ^a,b  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Phenoquest AG   (Germany)

Author keywords

Aerobic glycolysis; Brain metabolism; Metabolomics; Paroxetine; Proteomics; Time course

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; GLYCOGEN; INOSITOL; PAROXETINE; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METABOLISM; CHEMICAL ANALYSIS; CONTROLLED STUDY; DISEASE MARKER; ENERGY METABOLISM; GLYCOGEN METABOLISM; HIPPOCAMPUS; IN VIVO STUDY; MAJOR DEPRESSION; MALE; MASS SPECTROMETRY; METABOLOMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS;

EID: 84873524106     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.11.003     Document Type: Article

References (53)

1. Abdel-Razaq W., Kendall D.A., Bates T.E. The effects of antidepressants on mitochondrial function in a model cell system and isolated mitochondria. Neurochemistry Research 2011, 36:327-338.
2. Allaman I., Fiumelli H., Magistretti P.J., Martin J.L. Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes. Psychopharmacology (Berl) 2011, 216:75-84.
3. Banasr M., Duman R.S. Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biological Psychiatry 2008, 64:863-870.
4. Benjamini Y., Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B-methodological 1995, 57:289-300.
5. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nature Reviews Neuroscience 2006, 7:137-151.
6. Choi R.C., Siow N.L., Cheng A.W., Ling K.K., Tung E.K., Simon J., et al. ATP acts via P2Y1 receptors to stimulate acetylcholinesterase and acetylcholine receptor expression: transduction and transcription control. Journal of Neuroscience 2003, 23:4445-4456.
7. Ciccarelli R., Ballerini P., Sabatino G., Rathbone M.P., D'Onofrio M., Caciagli F., et al. Involvement of astrocytes in purine-mediated reparative processes in the brain. International Journal of Developmental Neuroscience 2001, 19:395-414.
8. Corodimas K.P., Tomita H. Adenosine A1 receptor activation selectively impairs the acquisition of contextual fear conditioning in rats. Behavioural Neuroscience 2001, 115:1283-1290.
9. Cox B., Emili A. Tissue subcellular fractionation and protein extraction for use in mass-spectrometry-based proteomics. Nature Protocols 2006, 1:1872-1878.
10. Curti C., Mingatto F.E., Polizello A.C., Galastri L.O., Uyemura S.A., Santos A.C. Fluoxetine interacts with the lipid bilayer of the inner membrane in isolated rat brain mitochondria, inhibiting electron transport and F1F0-ATPase activity. Molecular and Cellular Biochemistry 1999, 199:103-109.
11. DeBerardinis R.J., Lum J.J., Hatzivassiliou G., Thompson C.B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metabolism 2008, 7:11-20.
12. Erhardt A., Lucae S., Unschuld P.G., Ising M., Kern N., Salyakina D., et al. Association of polymorphisms in P2RX7 and CaMKKb with anxiety disorders. Journal of Affective Disorders 2007, 101:159-168.
13. Fields R.D., Burnstock G. Purinergic signalling in neuron-glia interactions. Nature Reviews Neuroscience 2006, 7:423-436.
14. Filiou M.D., Zhang Y., Teplytska L., Reckow S., Gormanns P., Maccarrone G., et al. Proteomics and metabolomics analysis of a trait anxiety mouse model reveals divergent mitochondrial pathways. Biological Psychiatry 2011, 70:1074-1082.
15. Fox P.T., Raichle M.E., Mintun M.A., Dence C. Nonoxidative glucose consumption during focal physiologic neural activity. Science 1988, 241:462-464.
16. Gruetter R. Glycogen: the forgotten cerebral energy store. Journal of Neuroscience Research 2003, 74:179-183.
17. Gu J.G., MacDermott A.B. Activation of ATP P2X receptors elicits glutamate release from sensory neuron synapses. Nature 1997, 389:749-753.
18. Hertz L., Peng L., Dienel G.A. Energy metabolism in astrocytes: high rate of oxidative metabolism and spatiotemporal dependence on glycolysis/glycogenolysis. Journal of Cerebral Blood Flow and Metabolism 2007, 27:219-249.
19. Hugel S., Schlichter R. Presynaptic P2X receptors facilitate inhibitory GABAergic transmission between cultured rat spinal cord dorsal horn neurons. Journal of Neuroscience 2000, 20:2121-2130.
20. Iosifescu D.V., Bolo N.R., Nierenberg A.A., Jensen J.E., Fava M., Renshaw P.F. Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder. Biological Psychiatry 2008, 63:1127-1134.
21. Iwata M., Shirayama Y., Ishida H., Hazama G.I., Nakagome K. Hippocampal astrocytes are necessary for antidepressant treatment of learned helplessness rats. Hippocampus 2011, 21:877-884.
22. Keller A., Shteynberg D. Software pipeline and data analysis for MS/MS proteomics: the trans-proteomic pipeline. Methods in Molecular Biology 2011, 694:169-189.
23. Khakh B.S. Molecular physiology of P2X receptors and ATP signalling at synapses. Nature Reviews Neuroscience 2001, 2:165-174.
24. Khakh B.S., North R.A. P2X receptors as cell-surface ATP sensors in health and disease. Nature 2006, 442:527-532.
25. Koppenol W.H., Bounds P.L., Dang C.V. Otto Warburg's contributions to current concepts of cancer metabolism. Nature Reviews Cancer 2011, 11:325-337.
26. Krystal J.H., Sanacora G., Blumberg H., Anand A., Charney D.S., Marek G., et al. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Molecular Psychiatry 2002, 7(Suppl. 1):S71-S80.
27. Kudryavtseva N.N., Bakshtanovskaya I.V., Koryakina L.A. Social model of depression in mice of C57BL/6J strain. Pharmacology Biochemistry and Behavior 1991, 38:315-320.
28. Lam P., Hong C.J., Tsai S.J. Association study of A2a adenosine receptor genetic polymorphism in panic disorder. Neuroscience Letters 2005, 378:98-101.
29. Lucae S., Salyakina D., Barden N., Harvey M., Gagne B., Labbe M., et al. P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. Human Molecular Genetics 2006, 15:2438-2445.
30. Magistretti P.J., Pellerin L., Martin J.L. Brain energy metabolism - an integrated cellular perspective, psychopharmacology - the fourth generation of progress 2000, The American College of Neuropsychopharmacology, 657-670.
31. McClatchy D.B., Dong M.Q., Wu C.C., Venable J.D., Yates J.R. 3rd. 15N metabolic labeling of mammalian tissue with slow protein turnover. Journal of Proteome Research 2007, 6:2005-2010.
32. Millstein R.A., Holmes A. Effects of repeated maternal separation on anxiety- and depression-related phenotypes in different mouse strains. Neuroscience and Biobehavioral Reviews 2007, 31:3-17.
33. Moretti A., Gorini A., Villa R.F. Affective disorders, antidepressant drugs and brain metabolism. Molecular Psychiatry 2003, 8:773-785.
34. Nag M., Nandi N. Antidepressants and brain respiration. Bioscience Reports 1991, 11:11-14.
35. Paixao S., Klein R. Neuron-astrocyte communication and synaptic plasticity. Current Opinion in Neurobiology 2010, 20:466-473.
36. Pan C., Kora G., McDonald W.H., Tabb D.L., VerBerkmoes N.C., Hurst G.B., et al. ProRata: a quantitative proteomics program for accurate protein abundance ratio estimation with confidence interval evaluation. Analytical Chemistry 2006, 78:7121-7131.
37. Renshaw P.F., Parow A.M., Hirashima F., Ke Y., Moore C.M., Frederick Bde B., et al. Multinuclear magnetic resonance spectroscopy studies of brain purines in major depression. American Journal of Psychiatry 2001, 158:2048-2055.
38. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
39. Scaini G., Maggi D.D., De-Nes B.T., Goncalves C.L., Ferreira G.K., Teodorak B.P., et al. Activity of mitochondrial respiratory chain is increased by chronic administration of antidepressants. Acta Neuropsychiatrica 2011, 23:112-118.
40. Sillaber I., Panhuysen M., Henniger M.S., Ohl F., Kuhne C., Putz B., et al. Profiling of behavioral changes and hippocampal gene expression in mice chronically treated with the SSRI paroxetine. Psychopharmacology (Berl) 2008, 200:557-572.
41. Swanson K.D., Reigh C., Landreth G.E. ATP-stimulated activation of the mitogen-activated protein kinases through ionotrophic P2X2 purinoreceptors in PC12 cells. Difference in purinoreceptor sensitivity in two PC12 cell lines. Journal of Biological Chemistry 1998, 273:19965-19971.
42. Vaishnavi S.N., Vlassenko A.G., Rundle M.M., Snyder A.Z., Mintun M.A., Raichle M.E. Regional aerobic glycolysis in the human brain. Proceedings of the National Academy of Sciences 2010, 107:17757-17762.
43. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
44. Vaughn A.E., Deshmukh M. Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. Nature Cell Biology 2008, 10:1477-1483.
45. Vlassenko A.G., Vaishnavi S.N., Couture L., Sacco D., Shannon B.J., Mach R.H., et al. Spatial correlation between brain aerobic glycolysis and amyloid-beta (Abeta) deposition. Proceedings of the National Academy of Sciences 2010, 107:17763-17767.
46. Warburg O., Posener K., Negelein E. On the metabolism of carcinoma cells. Biochemische Zeitschrift 1924, 152:309-344.
47. Webhofer C., Gormanns P., Tolstikov V., Zieglgänsberger W., Sillaber I., Holsboer F., et al. Metabolite profiling of antidepressant drug action reveals novel drug targets beyond monoamine elevation. Translational Psychiatry 2011, 1:e58.
48. Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 2005, 52:90-110.
49. Wu C.C., MacCoss M.J., Howell K.E., Matthews D.E., Yates J.R. 3rd. Metabolic labeling of mammalian organisms with stable isotopes for quantitative proteomic analysis. Analytical Chemistry 2004, 76:4951-4959.
50. Xia J., Psychogios N., Young N., Wishart D.S. MetaboAnalyst: a web server for metabolomic data analysis and interpretation. Nucleic Acids Research 2009, 37:W652-W660.
51. Yuan M., Breitkopf S.B., Yang X., Asara J.M. A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nature Protocols 2012, 7:872-881.
52. Zhang Y., Filiou M.D., Reckow S., Gormanns P., Maccarrone G., Kessler M.S., et al. Proteomic and metabolomic profiling of a trait anxiety mouse model implicate affected pathways. Molecular and Cellular Proteomics 2011, 10. M111 008110.
53. Zhang Y., Webhofer C., Reckow S., Filiou M.D., Maccarrone G., Turck C.W. A MS data search method for improved 15N-labeled protein identification. Proteomics 2009, 9:4265-4270.